The term “non-alcoholic steatohepatitis” (NASH) was originally used to describe liver damage characterized by lobular inflammation, steatosis and ballooning of hepatocytes. In addition, a large proportion of patients were described as having “cryptogenic cirrhosis” at the time: The term “non-alcoholic fatty liver disease” (NAFLD) was established as the diagnosis for these patients.
Autoren
- PD Dr. med. Sena Blümel
- Prof. Dr. med. Christoph Jüngst
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Type 1 Diabetes: A New Disease-Modifying Treatment Approach
Slowing the loss of β-cell function and delaying the progression of the disease
- Liver Cancer
Artificial Intelligence in Precision Oncology—Opportunities and Challenges
- Acute nonspecific back pain
Implementing a biopsychosocial approach
- Psychedelic-assisted therapy
Current status of PAT
- Neuropathic Pain
Evidence-Based Neuromodulation Based on Clinical Trials and Real-World Data
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Juvenile Idiopathic Arthritis
Early Detection and Targeted Treatment in an Interdisciplinary Setting
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib